Profusa, Inc.

Profusa, Inc. (Nasdaq: PFSA) is a bioelectronics company focused on developing injectable, tissue-integrating biosensor technology for continuous monitoring of body chemistry, including oxygen and other metabolic analytes, placing it squarely in the healthcare technology and medical devices sector. The company reached public markets through a SPAC merger and filed its annual report on Form 10-K with the Securities and Exchange Commission on February 26, 2024, accession number 0001213900-24-016600, reflecting its status as a post-merger reporting company. Profusa's platform targets clinical and consumer health applications with real-time, continuous physiological data. For full financials, SPAC deal history, and ownership analytics, sign up for access at SpacDesk.